These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28625005)

  • 21. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
    JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
    Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
    J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
    Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
    Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
    Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
    J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
    Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    Lemiński A; Kaczmarek K; Byrski T; Słojewski M
    PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
    Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
    Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
    Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
    Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
    Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.
    Kaimakliotis HZ; Monn MF; Cho JS; Pedrosa JA; Hahn NM; Albany C; Gellhaus PT; Cary KC; Masterson TA; Foster RS; Bihrle R; Cheng L; Koch MO
    Future Oncol; 2016 Aug; 12(15):1795-804. PubMed ID: 27255805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
    Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
    Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.